Sanofi is licensing a RadioMedix radiopharmaceutical in development for neuroendocrine tumors. The French pharmaceutical giant is responsible for global commercialization of the therapy, a potential competitor to the Novartis radiopharmaceutical Lutathera.
The post Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug appeared first on MedCity News.
